Quantbot Technologies LP Has $1.44 Million Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Quantbot Technologies LP decreased its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 65.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 4,328 shares of the company’s stock after selling 8,276 shares during the period. Quantbot Technologies LP’s holdings in Medpace were worth $1,438,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in MEDP. R Squared Ltd bought a new position in shares of Medpace during the 4th quarter valued at about $30,000. SBI Securities Co. Ltd. bought a new position in Medpace in the fourth quarter valued at approximately $31,000. Stone House Investment Management LLC acquired a new position in shares of Medpace in the third quarter valued at approximately $33,000. Jones Financial Companies Lllp boosted its holdings in shares of Medpace by 2,750.0% in the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock valued at $38,000 after buying an additional 110 shares during the period. Finally, Lindbrook Capital LLC increased its position in shares of Medpace by 27.6% during the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock worth $45,000 after acquiring an additional 29 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

MEDP opened at $330.59 on Tuesday. The business’s 50-day simple moving average is $337.29 and its 200 day simple moving average is $339.65. The firm has a market capitalization of $10.07 billion, a PE ratio of 26.17, a PEG ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a 52-week low of $302.01 and a 52-week high of $459.77.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. On average, research analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Analysts Set New Price Targets

MEDP has been the subject of a number of research analyst reports. Robert W. Baird upped their target price on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. Leerink Partners assumed coverage on Medpace in a report on Monday. They issued a “market perform” rating and a $330.00 price target on the stock. Eight investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, Medpace has a consensus rating of “Hold” and an average target price of $376.30.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.